ABRYSVO™ has been authorized for use in Canada for:

• Active immunization of pregnant individuals from 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age
• The prevention of LRTD caused by RSV in individuals 60 years of age and older by active immunization

NACI is reviewing the use of ABRYSVO™.

Arexvy has been authorized for use in Canada for the prevention of LRTD caused by RSV in adults 60 years of age and older.

NACI is reviewing the use of Arexvy.

NACI recommendations on RSV prophylaxis for infants are forthcoming, including further analysis of nirsevimab in relation to comparator interventions. Respiratory syncytial virus (RSV): Canadian Immunization Guide – Canada.ca